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Summary 
The decision to offer radiotherapy in patients with connective tissue diseases continues to be challenging. Radiotherapy 
might trigger the onset of connective tissue diseases by increasing the expression of self-antigens, diminishing regulatory 
T-cell activity, and activating effectors of innate immunity (dendritic cells) through Toll-like receptor-dependent 
mechanisms, all of which could potentially lead to breaks of immune tolerance. This potential risk has raised some debate 
among radiation oncologists about whether patients with connective tissue diseases can tolerate radiation as well as people 
without connective tissue diseases. Because the number of patients with cancer and connective tissue diseases needing 
radiotherapy will probably increase due to improvements in medical treatment and longer life expectancy, the issue of 
interactions between radiotherapy and connective tissue diseases needs to be clearer. In this Review, we discuss available 
data and evidence for patients with connective tissue diseases treated with radiotherapy. 
 
Introduction 
Connective tissue diseases are a heterogeneous group of autoimmune rheumatic diseases characterised by immune system 
dysregulation and the development of autoantibodies. Patients typically alternate between active or symptomatic periods 
and non-active or quiescent phases. Connective tissue diseases have historically been considered an absolute or relative 
contraindication to radiotherapy because of the hypothesis of a greater risk of severe radiotherapy-related acute and late 
complications. Few reports have been made of the outcomes of patients with newly diagnosed connective tissue diseases 
(or exacerbation of pre-existing disease) who need radiotherapy (Table 1 and Table 2).1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 
14, 15, 16, 17, 18, 19, 20 and 21 Although an analysis of the little available data shows that risk of radiotherapy toxicity in 
patients with connective tissue diseases seems to be based largely on anecdotal evidence, radiation oncologists remain 
hesitant. In 1998, the American College of Radiology22 concluded that, “a history of collagen vascular disease is a relative 
contraindication to breast conservation treatment because published reports indicate that such patients tolerate irradiation 
poorly. Most radiation oncologists will not treat patients with scleroderma or active systemic lupus erythematosus, 
considering either an absolute contraindication.” Thus, radiotherapy has been underused in patients with connective tissue 
diseases who have cancer.16 
With improved medical treatments, prognosis for patients with connective tissue diseases has improved. The 5-year 
survival in systemic lupus erythematosus has increased from about 40% in the 1950s, to 90% in the 1980s, to more than 
90–95% nowadays.23 Therefore, a higher number of patients with connective tissue diseases are expected to be diagnosed 
with cancer and will potentially be eligible for oncological treatment, including radiotherapy. Substantial improvements 
have been made in radiation technology, including the development of intensity-modulated radiotherapy and image-guided 
radiotherapy. These techniques are available in clinical practice, potentially minimising acute and late local side-effects. 
Thus, new radiotherapy techniques could be considered feasible even in patients with connective tissue diseases who have 
cancer. In this Review, we analyse evidence and discuss the available data for radiotherapy in patients with connective 
tissue diseases. 
 
Connective tissue diseases, cancer environments, and radiation interactions 
Connective tissue diseases are chronic and debilitating autoimmune disorders that cause substantial morbidity and mortality 
and disproportionately affect women. These diseases include rheumatoid arthritis, systemic sclerosis, scleroderma, systemic 
lupus erythematosus, dermatomyositis, and vasculitis. Connective tissue diseases often develop after environmental 
triggering via cellular pathways in genetically susceptible individuals with disease-associated polymorphisms.24 However, 
the specific cellular and molecular mechanisms leading to connective tissue diseases, and factors that establish involved 
organs are involved, are poorly understood. 
Associations between connective tissue diseases and cancer are being increasingly investigated. Links between them are 
multifaceted and have different relationships in terms of frequency, timing, and type of cancers. Several studies have 
highlighted the dynamic and bidirectional interactions occurring at the cancer–immune system interface that might be 
relevant to the origins of autoimmunity.25 Data for patients with systemic sclerosis and concomitant cancer suggest that, in 
some cases, autoimmunity might be triggered by an autoantigen mutation in the patient's cancer.26 and 27 Also, connective 
tissue diseases might cause changes in immune function that could be affected by immunosuppressive therapy.24 Although 
the evidence was not overwhelming, some investigators have reported that these changes in immune function did affect 
radiotherapy toxicity.28 This bidirectional hypothesis was based on the idea that some connective tissue diseases share a 
common pathological pathway of vascular obliteration and fibrosis due to heightened inflammation and a clinical pattern of 
possible systemic involvement. The potential for radiotherapy to augment these pathological changes became a topic of 
investigation. Radiotherapy acutely affects early responding tissues, such as the basal dermis and oral and gastric mucosa, 
by reducing proliferation. Radiation-induced obliteration of capillaries and small vessels is also well documented.28 In 
patients with connective tissue diseases, these acute effects might act in conjunction with immune-related damage caused 
by immune complex deposition, complement cascade activation, and infiltrating inflammatory cells (figure 1). Such 
common targeting might be additive to typical radiation-induced acute tissue injuries.11 The additive injury induced by 
both radiation and the pre-existing connective tissue diseases might also help to explain the potentially increased late 
effects noted in some of these patients after radiotherapy.3 Radiotherapy might trigger the onset of connective tissue 
diseases by enhancing the expression of self-antigens (eg, from apoptotic cell debris), diminishing regulatory T-cell 
activity, and activating effectors of innate immunity such as dendritic cells through Toll-like receptor-dependent 
mechanisms, all of which could potentially lead to a break of immune tolerance.25 This potential mechanism has raised a 
debate among radiation oncologists about whether patients with connective tissue diseases tolerate radiation as well as 
people with no connective tissue disease.29 
Experimental evidence supports the hypothesis that the immune system is able to repress tumour cells and that immune 
surveillance has a key role in the identification and elimination of cancer cells.30 Three different phases have been 
described in the interaction between cancer cells and the immune system: elimination (which is still considered the 
cornerstone in the immune surveillance process), equilibrium between the immune system and cancer cells, and escape.30 
Immune surveillance is considered a complex process involving different immune system cells—ie, CD8 cells, natural 
killer cells, CD4 cells, macrophages, and B lymphocytes.30 After radiotherapy, the disruption of the tissue architecture is 
associated with changes in blood flow (zones with hyperperfusion and hypoxia) and lymphatic function and an increase in 
interstitial pressure.31 Additionally, irradiation of the tumour and its microenvironment is associated with the proliferation 
of inflammatory signals detected by the immune system.32 The resulting production of cytokines and chemokines then 
attracts antigen-presenting cells (dendritic cells) that, after uptake of tumour-associated antigens, cause CD8 activation 
involved in tumour killing (figure 1).33 and 34 
Evidence is also increasing that inflammation contributes to cancer development and that cancer cells use inflammatory 
mechanisms to prevent immune-system activation and to protect the tumour from immune attack (equilibrium and escape 
phases).35 Moreover, inflammatory elements (such as chemokines and interleukins) released by tumour cells promote 
infiltration, progression of disease, and metastases (figure 2).36 
Various mechanisms might exist that exacerbate the pathophysiological response induced by radiation exposure in patients 
with connective tissue diseases. One potential mechanism includes the overexpression of profibrotic cytokines, such as 
transforming growth factor β (TGFβ) and interleukin 1. Radiation injury in healthy tissues is usually characterised by the 
appearance of a fibrinous exudate within the stroma and by deposition of extracellular matrix components, including 
collagen, through myofibroblasts produced by fibroblast activation and differentiation.37 In some connective tissue 
diseases (such as systemic sclerosis) in which TGFβ concentrations are already increased, late effects after radiotherapy 
might be more evident.3 Another potential mechanism involves radiation microvascular damage in a context of vasculitis, 
leading to increased late effects and reduced tolerance to treatment. After radiation, endothelial cell injury and tissue 
hypoxia stimulate the recruitment into the tissue of inflammatory circulating cells, such as macrophages, which are a source 
of profibrotic mediators, including TGFβ1.38 and 39 Additionally, increased concentrations of proangiogenesis factors (eg, 
VEGF) as a result of vascular damage and leakage of vessels in response to radiotherapy could exacerbate late effects such 
as dermal atrophy, telangectasia, necrosis, and fibrosis.40 Finally, radiation-induced damage to basement membranes 
causes this to become a target tissue, leading to increased autoimmunity.12 and 28 
 
Preclinical studies and case reports 
Some studies have used in-vitro sensitivity to radiation in lymphocytes from patients with connective tissue diseases to 
assess risk indicators for radiation-related side-effects.41, 42 and 43 Carrillo-Alascio and colleagues41 used pulsed-field 
gel electrophoresis to quantify the initial radiation-induced DNA double-strand breaks in peripheral lymphocytes from 52 
patients with systemic lupus erythematosus. Systemic lupus erythematosus did not confer a higher intrinsic risk of 
radiosensitivity when compared with 48 healthy participants without connective tissue diseases.41 In another study,43 the 
same investigators carried out an in-vitro evaluation of the repair of mainly single-stranded DNA breaks after peripheral 
blood radiation of 48 children with systemic lupus erythematosus, systemic sclerosis, juvenile rheumatoid arthritis, and 
dermatomyositis. Greater DNA damage and a delay in DNA repair were noted in the children with connective tissue 
diseases group than in healthy children.43 Another in-vitro study that used tritiated thymidine incorporation assays showed 
that patients with active systemic lupus erythematosus had increased radiotherapy-related lymphocytic sensitivity when 
compared with healthy patients when irradiated with 60Co-γ photons between 0 Gy and 10 Gy, resulting in a potentially 
higher probability of radiation toxicity.42 
Similarly, immune system changes, which can affect radiosensitivity, are being investigated. Among others, Budach and 
colleagues44 investigated the possibly abnormal reaction to high radiation doses in two groups of germline mutation-
carrying mice, one with severe combined immunodeficiency (SCID; even though it is not classified as a connective tissue 
disease) and one that had normal radiation sensitivity (C3H). The lethal dose for 50% of the irradiated animals after single-
dose whole-body irradiation was lower for SCID mice than for C3H mice, as was the radiation dose that was needed to 
achieve 50% local control and tumour growth delay, thus confirming that abnormal radiation sensitivity was observed in 
SCID mice.44 A possible mechanism correlated with increased sensitivity of SCID tumour cell lines is the inability of the 
tumour cells to overcome their genetic deficiency in DNA double-strand break repair in SCID fibroblasts.45 
More than 300 cases involving patients with connective tissue diseases have been published reporting toxicity after 
radiotherapy and several early and late radiotherapy-related complications, including some deaths, have also been 
reported.2, 5, 7, 10 and 46 The first two severe events in patients with connective tissue diseases given radiotherapy were 
noted in the late 1960s.47 and 48 In one case, a patient with systemic lupus erythematosus who had lymphoma died of 
heart failure 1 year after radiotherapy to the mediastinal and retroclavicular nodes (20 Rad [20 Gy] and 39 Rad [39 Gy], 
respectively, with 60Co),47 whereas the second patient, who had facial lupus, developed radiotherapy-correlated 
osteomyelitis of the maxilla.48 However, no data about radiotherapy dose or modality were provided. Teo and colleagues1 
assessed the radiation toxicity profiles of ten patients with a diagnosis of early-stage nasopharyngeal carcinoma and 
dermatomyositis (table 1). At a median follow-up of 51·8 months, all patients had subcutaneous fibrosis and xerostomia, 
two patients had radiation skin necrosis, and one patient had a VI and XII cranial nerve deficit.1 However, no information 
was provided about radiotherapy dose and techniques. 
Fleck and colleagues2 published a study of nine patients with breast cancer (four women with a pre-existing connective 
tissue disease and five who developed a connective tissue disease after radiotherapy). Eight received radiotherapy using 
60Co with a prescription dose of 40–50 Gy and an electron boost on the tumour bed of 5–15 Gy. Three patients with a pre-
existing connective tissue disease reported a severe toxicity profile: the first case involved moist desquamation and brachial 
plexopathy; the second case showed soft-tissue necrosis needing chest-wall resection, rib fractures, and pulmonary fibrosis; 
and the third patient had soft-tissue necrosis, bronchopleural–cutaneous fistula, and osteonecrosis of the clavicle, sternum, 
and rib. None of the patients with a new diagnosis of connective tissue diseases after radiotherapy had severe 
complications.2 
According to McCormick,49 to reduce the side-effects in patients with connective tissue disease and breast cancer, a more 
aggressive local surgery and systemic therapy, in particular for younger women (<40 years), was better than breast-
conserving surgery followed by radiation. More recently, accelerated partial breast irradiation by either brachytherapy or 
intraoperative radiotherapy has been considered an alternative experimental option for the treatment of early-stage breast 
cancer in women with a history of connective tissue diseases. Dragun and colleagues9 published a report of nine patients 
with connective tissue diseases with breast cancer given accelerated partial breast irradiation via high-dose brachytherapy; 
toxicity and cosmetic profiles were reported as satisfactory. Indeed, the authors concluded that it might not be necessary to 
exclude patients with connective tissue diseases from clinical trials of accelerated partial breast irradiation. As 
confirmation, Turesson and colleagues6 reported that autoimmune disease did not increase the risk of skin teleangectasia in 
35 patients who received radiotherapy for breast cancer. Finally, Lowell and colleagues10 published data on the use of a 
very high dose of radiation delivered with gamma knife for brain metastases in 14 patients with connective tissue diseases, 
and reported no grade 3 or 4 toxicity (table 1). 
In conclusion, in-vitro studies and clinical case reports describe a narrow and heterogeneous picture for patients with 
connective tissue diseases who receive radiotherapy. Despite these data limitations, more recently published data show that 
patients with connective tissue diseases seem to be less affected by toxicity than are healthy individuals and case reports 
(table 1). 
 
Retrospective and controlled studies 
To our knowledge, no randomised controlled study has assessed whether patients with connective tissue diseases are more 
likely to develop acute or late radiotherapy-related toxicity. However, we retrieved 11 case series.11, 12, 13, 14, 15, 16, 17, 
18, 19, 20 and 21 In a retrospective analysis, Morris and Powell12 reported a large series of 209 patients with connective 
tissue diseases given radiotherapy with a median radiation dose of 45 Gy (range 13–82) between 1960 and 1995. After a 
median follow-up of 6 years, clinically significant acute side-effects (Radiation Therapy Oncology Group/Eastern 
Cooperative Oncology Group RTOG/ECOG Early Morbidity Scoring Scale of more than three) were similar in patients 
with and without rheumatoid arthritis (both 12%). At 5 years, the risk of late morbidity for patients with rheumatoid 
arthritis was 6%, similar to the rate for the healthy population generally, whereas for patients without rheumatoid arthritis it 
was 21% (p=0·0002). The most highly represented connective tissue disease after rheumatoid arthritis was systemic lupus 
erythematosus, with 25 patients (12%). No correlation between dose, fraction size, irradiated volume, and late effects were 
reported.12 
Similar results were reported in a matched-control study of 61 patients with connective tissue diseases.11 The number of 
acute reactions after radiotherapy in the connective tissue diseases group was only slightly higher than in the matched-
control group, with grade 3 or greater acute toxicity noted in seven patients in the connective tissue diseases group and four 
in the matched-control group. Patients with systemic lupus erythematosus had an increase in the number of acute reactions 
due to radiation (36% of patients with systemic lupus erythematosus vs 18% in the control group, p=0·5), whereas patients 
with rheumatoid arthritis had an increase in late complications (24% vs 5%; p=0·125). Nevertheless, the study showed no 
significant differences in acute and late toxicity complications between groups. 11 
Chen and colleagues13 reported no significant differences in acute complications after breast cancer radiotherapy between 
a group of 36 women with connective tissue diseases and a matched-control group (14% vs 8%, respectively; p=0·40), but 
did note a significant difference in late toxicity in those patients with connective tissue diseases (17% vs 3%; p=0·0095). 
However, when the investigators stratified patients by specific autoimmune disease, they found a significant difference 
only in four patients with scleroderma. 13 Phan and colleagues14 assessed 76 patients who received radiation for cancer 
(38 patients with connective tissue diseases and 38 in the control group) and did not show any significant differences in 
terms of acute or late complications between groups. However, increased risk of radiation complications was reported in 
patients with scleroderma (n=4). 
In another study, Lin and colleagues18 reported toxic effects in 73 patients with connective tissue diseases given 
radiotherapy. No differences were noted in acute toxicity between patients with connective tissue diseases and those in the 
control group. However, patients with a diagnosis of connective tissue diseases had a significantly higher incidence of late 
toxicity compared with the control group (29% vs 14%, respectively; p=0·001), with a non-significant increase in severe 
late toxicity (9% vs 4%; p=0·079). Patients with diagnosed connective tissue diseases who received radiation to the pelvis 
had a higher probability of severe toxicity reactions (grade 3 or higher); furthermore, the incidence of severe late toxicity 
was higher in patients with a diagnosis of systemic lupus erythematosus and scleroderma than in the control group. 18 
Gold and colleagues19 retrospectively analysed the toxicity profile of 41 patients with connective tissue diseases given 
radiation for cancer (20 patients with systemic sclerosis and 21 patients with systemic lupus erythematosus). Patients were 
divided into high-severity and low-severity connective tissue diseases on the basis of the number of involved organs. 
Univariate analysis showed a significant increase in the risk of any grade toxicity for patients with high-severity connective 
tissue diseases compared with those with low-severity connective tissue diseases (p=0·006), although no differences in 
grade 3 or higher toxicity were found between the two groups (p=0·56). Despite the small number of enrolled patients, the 
severity of connective tissue diseases could be considered as an important factor in the prediction of treatment tolerability. 
Nonetheless, the severity of connective tissue diseases was not a clear contraindication to radiotherapy.19 
Varga and colleagues3 reported on the toxicity profile of four patients with systemic sclerosis who were given 
radiotherapy.3 All patients had cutaneous and subcutaneous late toxicity, visceral fibrotic reactions at the radiation site, and 
severe skin toxicity and fibrosis extending beyond the radiation field involving internal organs. Three of the four patients 
subsequently died, two from bowel obstruction and one from pneumonia.3 
Liu and colleagues15 planned a prospective study to investigate the effect of neoadjuvant androgen-deprivation therapy and 
radiotherapy in men with prostate cancer. A subanalysis showed that 15 of the men had a connective tissue disease and that 
these patients had a greater frequency of late genitourinary grade 2 toxicities compared with healthy men (relative risk 
3·98; p=0·007).15  
As previously stated, several studies have reported radiotherapy-related toxicity profiles in patients with a range of 
connective tissue diseases (Table 1 and Table 2). Nevertheless, only a few of the studies7, 8, 17 and 20 focused on patients 
with scleroderma and systemic lupus erythematosus, with contentious conclusions about radiotherapy toxicity. Gold and 
colleagues17 assessed the toxicity profiles of 20 patients with scleroderma and cancer who had been treated with 
radiotherapy or brachytherapy or both, with or without concurrent chemotherapy. Univariate analysis showed a significant 
association between acute toxicity, radiotherapy dose, and increased scleroderma involvement of organs. For late side-
effects, negative antinuclear antibody serology was correlated with a higher probability of toxicity. None of the analysed 
pretreatment and treatment variables were correlated with severe acute and late toxicity.17 There have been no further 
reports to confirm severe acute and late complication profiles in this specific setting.7, 8 and 10 Rakfal and Deutsch7 
described data for six patients who had a diagnosis of systemic lupus erythematosus and different malignancies with 
various radiotherapy doses, reporting no unexpected severe acute or late side-effects. Khoo and colleagues8 reported no 
relevant acute or late complications in two patients with anal cancer with systemic lupus erythematosus taking concomitant 
immunosuppressive therapy who were treated with combined chemoradiotherapy (60Co and external-beam radiotherapy). 
One of the most important reports was published by Pinn and colleagues,20 which included 21 patients with systemic lupus 
erythematosus who received a total of 35 consecutive courses of radiotherapy. Of the 17 patients who were evaluable for 
late toxicity, four patients (24%) had a grade 3 or higher toxicity. The presence of renal involvement according to the 
American Rheumatism Association criteria was correlated with an increased risk of any grade of late toxicity (p<0·006). 
Univariate analysis established a correlation between acute toxicity and total dose (>49·8 Gy), treatment sites, and curative 
intent for treatment. Brachytherapy was used in one treatment course, 2D radiotherapy in 30 courses, 3D conformal 
radiotherapy in three, and intensity-modulated radiotherapy in one. Moreover, absence of photosensitivity (p<0·02), 
absence of arthritis (p<0·03), and presence of a malar rash (p<0·04) were correlated with an increased risk of grade 3 or 
greater acute toxicity. No specific association between technique and late toxicity was noted. Radiation dose prescription, 
radiation techniques, and anatomical site (ie, abdomen, pelvis, breast, brain, neck, and chest) were associated with a high 
risk of any late toxicity. In conclusion, the small number of described cases and the heterogeneity of the connective tissue 
disease seem to strongly affect the statistical power of these studies, thus limiting the possibility to show any robust 
association between radiation toxicity and connective tissue diseases, and confirming that radiotherapy is frequently 
withheld unjustly to treat patients with connective tissue diseases.16, 19 and 21 
 
Clinical solutions and future perspectives 
Various treatment strategies have been considered for patients with connective tissue diseases to reduce the risk of toxicity 
during or after radiotherapy such as avoiding concomitant treatment or reducing dose prescription. Although the use of 
chemoradiotherapy is considered the gold standard in many cases, multimodality treatment in patients with connective 
tissue diseases could be correlated with a more severe toxicity profile than single-modality treatment, thereby affecting its 
feasibility.4, 12, 19 and 50 In radiotherapy, the radiation dose could be reduced to lower the toxicity profile, but this could 
impair effectiveness.12, 28, 44 and 51 However, Delanian and colleagues52 reported that reducing radiation dose (from 65 
Gy to 40 Gy) in patients with connective tissue diseases (one with lung cancer and two with anal–rectal cancer) resulted in 
complete remission, although side-effects were observed at the radiation site. Some investigators have postulated that 
hyperactivation of the immune system by tumour cells makes patients with connective tissue diseases more sensitive to 
radiation than others.53 and 54 Another strategy is changing dose fractionation schedules or reducing treatment volume, 
which might decrease toxicity complications.2, 12, 28, 40, 51, 52 and 54 Nevertheless, a crucial question still remains—is 
it really necessary to modify radiotherapy features to decrease toxicity in patients with connective tissue diseases? The 
most common radiotherapy approach is to use external beams to deliver ionising radiation. In the past few decades, most 
departments have replaced their 60Co machines with the more precise linear accelerator. Despite modern radiotherapy now 
being available, most reports of patients with connective tissue diseases involve obsolete and unsatisfactory technologies 
including 2D radiotherapy. Intensity-modulated radiotherapy and stereotactic ablative radiotherapy have allowed radiation 
oncologists to prescribe higher dose prescriptions to targets when useful or required. Intensity-modulated radiotherapy is 
considered an advancement of 3D-conformal radiotherapy that targets the radiation dose into the tumour, thus minimising 
the exposure of healthy tissue in several anatomical regions. Intensity-modulated radiotherapy is considered the most 
appropriate technique in head and neck cancers and in most pelvic tumours, including prostate cancer. In this disease, 
intensity-modulated radiotherapy decreased long-term toxicity with no negative effect on overall survival when compared 
with 3D-conformal radiotherapy.54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65 and 66. 
Stereotactic ablative radiotherapy is a novel radiotherapy method that delivers a very high dose of radiation (in a single or a 
few fractions) with high precision to the tumour, thus maximising the sparing of surrounding normal tissue. Several 
retrospective and prospective stereotactic ablative radiotherapy studies have shown promising results in terms of local 
tumour control and survival in some settings, including in early non-small-cell lung cancer.67 Moreover, image-guided 
radiotherapy based on daily patient set-up position verification allowed better definition of the tumour target to reduce and 
ultimately eliminate uncertainties. To our knowledge, no randomised controlled trials using image-guided radiotherapy 
have assessed toxicity and efficacy in patients with connective tissue disease. Hence, the promising, modern techniques 
could improve radiotherapy tolerability, especially in challenging clinical situations, as well as in patients with connective 
tissue diseases and cancer.68 and 69 
 
Conclusion 
The data that are currently available from case series and a few retrospective studies are still not enough to support a 
specific contraindication for radiotherapy in patients with connective tissue diseases. Nevertheless, a cautious approach for 
patients with active connective tissue diseases seems to be reasonable. Moreover, the recent implementation of new 
radiotherapy approaches could be promising to improve the feasibility and tolerability of radiotherapy in some patients with 
cancer, including those with connective tissue diseases. Further well designed prospective studies, which also assess the 
most appropriate total dose and fractionation schedules, will probably help to overcome the unresolved concerns about 
radiotherapy indication for patients with connective tissue diseases. 
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Tumour 
type 
Patients with 
connective 
tissue disease 
(n) 
Type of connective 
tissue disease 
Increase in 
severe acute 
toxicity 
Increase in 
severe late 
toxicity 
Treatment Conclusion 
Teo et al, 
19891 
Head and 
neck 
10 Dermatomyositis Yes Yes External-beam 
radiotherapy 
Effect 
Fleck et al, 
19892 
Breast 9 Mixed Yes Yes External-beam 
radiotherapy 
Effect 
Varga et al, 
19913 
Mixed 4 Progressive systemic 
sclerosis 
No Yes External-beam 
radiotherapy 
Effect 
Hareyama et 
al, 19954 
Head and 
neck 
2 Mixed Yes No Concurrent 
chemotherapy and 
external-beam 
radiotherapy 
Inconclusive* 
Bliss et al, 
19965 
Cervix 5 Mixed Yes No External-beam 
radiotherapy and 
brachytherapy 
Effect 
Turesson et 
al, 19966 
Breast 35 NA NA No NA No effect 
Rakfal and 
Deutsch, 
19987 
Mixed 6 Systemic lupus 
erythematosus, discoid 
lupus erythematosus 
No No External-beam 
radiotherapy 
No effect 
Khoo et al, 
20048 
Anal 
cancer 
2 Systemic lupus 
erythematosus 
No No Concurrent 
chemotherapy and 
external-beam 
radiotherapy 
No effect 
Dragun et al, 
20119 
Breast 9 Mixed No No Intraoperative 
radiotherapy and 
brachytherapy 
No effect 
Lowell et al, 
201110 
Brain 
metastases 
14 Mixed No No Gamma knife No effect 
 
Table 1. 
Patient characteristics and findings from selected case studies of patients with connective tissue diseases and cancer 
reporting toxicity 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Primary 
tumour 
site 
Patients 
with 
connective 
tissue 
disease (n) 
Type of 
connective 
tissue disease 
(n) 
Study 
design 
Increase in 
severe 
acute 
toxicity 
Increase in 
severe late 
toxicity 
Median 
radiotherapy 
dose 
Radiotherapy 
technique Conclusion 
Ross et 
al, 
199311 
Mixed 61 Rheumatoid 
arthritis 
(n=39), 
systemic lupus 
erythematosus 
(n=13), other 
(n=9) 
Matched 
pair 
analysis 
No No 56 Gy External-beam 
radiotherapy, 
brachytherapy 
No effect 
Morris 
et al, 
199712 
Mixed 209 Rheumatoid 
arthritis 
(n=131), 
systemic lupus 
erythematosus 
(n=25), other 
(n=53) 
Retrospect
ive 
No Yes 45 Gy External-beam 
radiotherapy 
Inconclusive* 
Chen 
et al, 
200113 
Breast 36 Rheumatoid 
arthritis 
(n=17), 
systemic lupus 
erythematosus 
(n=5), 
scleroderma 
(n=4), other 
(n=10) 
Matched 
pair 
analysis 
Yes Yes 64 Gy External-beam 
radiotherapy, 
brachytherapy 
No effect 
(effect in 
scleroderma) 
Phan 
et al, 
200314 
Mixed 38 Systemic lupus 
erythematosus 
(n=21), 
scleroderma 
(n=2), other 
(n=15) 
Matched 
pair 
analysis 
No No 55·17 Gy External-beam 
radiotherapy, 
brachytherapy 
No effect 
(effect in 
scleroderma) 
Liu et 
al, 
200415 
Prostate 15 NA Prospectiv
e 
No Yes 66 Gy External-beam 
radiotherapy 
Effect 
Benk 
et al, 
200516 
Mixed 38 Systemic lupus 
erythematosus 
(n=38; 4 
radiotherapy 
treated) 
Retrospect
ive 
No No NA NA No effect 
Gold 
et al, 
200717 
Mixed 20 Scleroderma 
(n=20) 
Retrospect
ive 
No No 36 Gy External-beam 
radiotherapy, 
brachytherapy 
No effect 
Lin et 
al, 
200818 
Mixed 73 Rheumatoid 
arthritis 
(n=33), 
systemic lupus 
erythematosus 
(n=13), 
scleroderma 
Retrospect
ive 
No Yes NA External-beam 
radiotherapy 
No effect 
(effect 
unknown in 
pelvic site 
systemic lupus 
erythematosus 
or 
 Primary 
tumour 
site 
Patients 
with 
connective 
tissue 
disease (n) 
Type of 
connective 
tissue disease 
(n) 
Study 
design 
Increase in 
severe 
acute 
toxicity 
Increase in 
severe late 
toxicity 
Median 
radiotherapy 
dose 
Radiotherapy 
technique Conclusion 
(n=9), other 
(n=18) 
scleroderma) 
Gold 
et al, 
200819 
Mixed 41 Progressive 
systemic 
sclerosis 
(n=20), 
systemic lupus 
erythematosus 
(n=21) 
Retrospect
ive 
NA No NA External-beam 
radiotherapy, 
brachytherapy 
Inconclusive* 
Pinn et 
al, 
200820 
Mixed 21 Systemic lupus 
erythematosus 
(n=21) 
Retrospect
ive 
Yes No 49·75 Gy External-beam 
radiotherapy, 
brachytherapy, 
intensity-
modulated 
radiotherapy 
No effect 
Patel 
et al, 
201221 
Mixed 12 Discoid lupus 
erythematosis 
(n=12) 
Retrospect
ive 
No No 69 Gy External-beam 
radiotherapy, 
brachytherapy 
No effect 
Table 2. 
Effect of connective tissue diseases on toxicity after cancer treatments reported in retrospective and matched pair studies 
 
 
 
 
Figure 1: Main immune cells, interleukins, and cytokines involved in immune surveillance TGF=transforming growth 
factor. IFN=interferon. IL=interleukin. TNF=tumour necrosis factor 
 
 
 
 
 
 
 
Figure 2: Tumour-cell mechanisms against the immune system TGF=transforming growth factor. CXC=CXC chemokine. 
IFN=interferon. IL=interleukin. TNF=tumour necrosis factor. 
